Quantcast

Latest Access Pharmaceuticals Inc. Stories

2010-06-10 07:30:00

DALLAS, June 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Senior VP of R&D, David Nowotnik, Ph.D., will give two presentations today on the Company's Cobalamin siRNA program at the Novel Nanodelivery of siRNA and miRNA Symposium, hosted by the California NanoSystems Institute (CNSI) of UCLA. Access Pharma's invited oral presentation and its...

2010-05-19 14:02:00

DALLAS and NEW YORK, May 19 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research initiated coverage on the Company with an "Outperform" and a 12-month price target of $8.00. The report can be viewed by clicking on following link: http://www.accesspharma.com/downloads/analyst-reports/ACCPInitiation.pdf About Zacks: Founded in...

2010-04-21 07:30:00

DALLAS and NEW YORK, April 21 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis,...

2010-04-19 07:30:00

DALLAS and NEW YORK, April 19 /PRNewswire-FirstCall/ -- Jeffrey Davis, President and CEO of ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, was recently interviewed by the Proactive Investors Group, an international financial media company. In the interview, Davis provides an overview of Access Pharma's robust product pipeline, an update on the global rollout of its FDA-approved product MuGard,...

2010-04-15 07:30:00

DALLAS and NEW YORK, April 15 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis ("OM"), Stephen T. Sonis, DMD, DMSc, Chief of the Division of Oral Medicine at the Dana Farber Cancer Institute and Program Director for Supportive Cancer Care at Clinical Assistance Programs, LLC ("CAP"), to further...

2010-04-13 07:30:00

DALLAS and NEW YORK, April 13 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it has completed its first commercial scale production run of MuGard in North America at Accupac, Inc. manufacturing facilities outside Philadelphia. Access intends to use the initial batches of MuGard for pre-launch key institution evaluations, preliminary stock for select wholesalers and specialty distributors, and additional post-approval studies to be conducted...

2010-03-30 07:30:00

DALLAS, March 30 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin(TM)-based oral insulin and other Cobalamin-based products. A major focus of this program will be a first-in-man study for Access' oral insulin product. The study is an important step...

2010-03-25 07:30:00

DALLAS, March 25 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that JCOM Co., Ltd., its Korean licensee for both MuGard(TM) and ProLindac(TM), has received approval from the Korean Food and Drug Administration (KFDA) of its Registration Dossier for MuGard, an oncology supportive-care treatment for the management of oral mucositis. Under the agreement, JCOM is responsible for obtaining the necessary regulatory approvals for MuGard in Korea....

2010-03-11 07:30:00

DALLAS, March 11 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin(TM) Oral Drug Delivery Technology. Access previously reported that its novel Cobalamin-coated...

2010-02-04 08:00:00

DALLAS, Feb. 4 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related